Syndax Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
&-
All right. Let's get started, and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by my squad, Priyanka Grover, [Le Re Hall], Malcolm Kuno. Our next presenting company is Syndax and presenting on behalf of the company, we have CEO, Michael Metzger. Michael?
Thank you, Anupam. Thank you, JPMorgan, for having us to this year's conference. So we a pleasure to present to you all of you today and give you an update on our progress. It's been a really very exciting year as Anupam said, I'm Michael Metzger, CEO of the company. So this is our forward-looking disclosure as others. We are making forward-looking statements today. I ask you to refer to our SEC documents for further information related to forward-looking statements.
I'll start off today talking a little bit about our two programs, actually a lot about our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |